A késői kezdetű Pompe-kórban szenvedők enzimpótló kezelésének hosszú távú követése
Mária Judit Molnár(Istituto delle Scienze Neurologiche di Bologna), Judit Bidló(National Healthcare Service Center), Lívia Dézsi(University of Szeged), Zsuzsanna Almássy(Boston Children's Hospital), Zoltán Grosz(Semmelweis University), Zita Jobbágy(Bács-Kiskun Megyei Kórház), Laszló Jávor(Petz Aladár Megyei Oktató Kórház), Levente Kerényi(Fejér Megyei Szent György Egyetemi Oktató Kórház), Ágnes Sebök(University of Pecs)
Cited by 4
Related Papers
Mucopolysaccharidosis type II: European recommendations for the diagnosis and multidisciplinary management of a rare disease
|Orphanet Journal of Rare Diseases|2011|237
Mortality and cause of death in mucopolysaccharidosis type II—a historical review based on data from the Hunter Outcome Survey (HOS)
|Journal of Inherited Metabolic Disease|2009|183
The present state and perspectives of micronucleus assay in radiation protection. A review
|International Journal of Radiation Applications and Instrumentation Part A Applied Radiation and Isotopes|1987|112
Efficacy and Safety of Elamipretide in Individuals With Primary Mitochondrial Myopathy
|Neurology|2023|74
A population‐based epidemiological study of neuromyelitis optica spectrum disorder in Hungary
|European Journal of Neurology|2019|41